Retrospective Data Collection Study in Patients With Macular Oedema Receiving OZURDEX®

Allergan

Status: Completed

Conditions: Macular Edema; Retinal Vein Occlusion

Treatments: Other: No Intervention

Study type: Observational

Funder types: Industry

Identifiers

NCT02181530

MAF/AGN/OPH/RET/016

Details and patient eligibility

About

This study will use retrospective data to evaluate the safety and efficacy of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) in the treatment of macular oedema due to retinal vein occlusion (RVO) in clinical practice. No intervention will be administered as part of this study.

Enrollment: 43 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Macular oedema in at least one eye due to branch retinal vein occlusion (BRVO) or central vein occlusion (CRVO)
• Received at least one injection of OZURDEX® in the study eye

Exclusion criteria

• None

Trial design

43 participants in 1 patient group

OZURDEX®

Description:

Retrospective data collection study of OZURDEX® (dexamethasone intravitreal implant 0.7 mg) administered at least once in accordance with routine clinical practice. No treatment (intervention) is administered as part of this study.

Treatment:

Other: No Intervention